Brain Metastases Clinical Trial
— SPEEDOfficial title:
Protocol for Evaluating a Planning Algorithm for Gamma Knife Radiosurgery
The process of developing Gamma Knife radiosurgery treatment plans is today very dependent on
the level of human expertise resulting in a great heterogeneity of the intrinsic qualities of
the treatment planning and the quality of care delivered in radiosurgery.
The existing reverse planning systems, although they have progressed considerably in recent
years, produce results that are still lower than those achieved by an expert.
Conventionally, an experienced dosimetric planner will act mainly on the coordinates of the
position of the isocenters, on the size of the collimators, sector by sector, and on the
irradiation time of each isocenters. In theory, the combination of these variables provides
access to billions of combinatorics whose diversity far exceeds the computational
capabilities of the human mind. The dosimetric planner therefore uses a very small part of
the spectrum of possible patterns by always reproducing a limited number of empirical
solutions.
The company Intuitive Therapeutics has developed a new mathematical algorithm which can
automatically test in a very short time all the combinatorial possibilities and converge very
quickly to the solution that best meets the clinical, anatomical and dosimetric objectives
defined by the neurosurgeon. The quick processing of the system also allows the operator to
modify the constraints to refine the proposed result in real time.
The demonstration of the reality of the performances of this algorithm would give the ability
to even inexperienced users to develop high performance planning for the benefit of the
patient in terms of optimizing the efficacy / toxicity ratio of the radiosurgery treatment
results
The primary objective is to evaluate comparatively the quality of the schedules produced by
the algorithm developed by the company Innovative Therapeutics to those produced by an expert
who carried out more than 15000 dosimetric plannings and radiosurgical interventions.
The main criterion of comparison is the Paddick index.
The secondary criteria for comparison are:
- Compliance index
- selectivity index
- Gradient index
- Maximum, minimum, average dose at risk structures
- Dose distribution in the target volume
- Treatment time (at equal source activity)
- Time of realization of the planning
It was chosen to treat patients with vestibular Schwannoma OR multiple brain metastases (> 5)
treated in single session by Gamma Knife OR para-optic meningioma in hypo-fractionated
treatment on Gamma Knife with restraint mask with inclusion of visual paths in the target
volume planning.
The aim of the study is to show at least the non-inferiority of this new method compared to
the expert user based on the Paddick Index. This index has continuous values between 0 and 1,
0 being the worst case and 1 being the ideal solution. In order to define the sample size
needed for each pathology, a pilot phase is required. This phase can be performed
retrospectively using treatments already defined by the expert user. This pilot phase will
allow us to identify the difference that can be expected between the index values and the
variability of this difference. Based on these values we will be able to determine the size
of the sample allowing us to statistically test the non-inferiority, or even the superiority
of this new device. The number of cases to be included during the pilot phase should be at
least ten cases and a maximum of thirty cases. The choice of the number of cases to be
integrated during this pilot phase will depend on the homogeneity of the differences obtained
on the first cases. These values will allow us to calculate the size of the samples necessary
for the study of non-inferiority as well as for the study of superiority. Depending on the
calculated sizes samples we will make a choice to ensure that this study takes place in the
expected duration.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | January 10, 2020 |
Est. primary completion date | January 10, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female at least 18 years old - Patient treated for Gamma Knife - Patient who has benefited or needs Gamma-Knife radiosurgical treatment - Patient affiliated to a social protection scheme. - Patient having understood the information notice and expressed his non opposition. Exclusion Criteria: - Patient with a contraindication to perform a brain MRI - Patient with a contraindication to radiosurgical treatment (previous treatment with cerebral radiotherapy) - Pregnant and lactating women - Simultaneous participation in another therapeutic trial or in the exclusion period of a previous clinical trial. - Vulnerable persons: minors, protected adults (guardianship or trusteeship) and adults unable to express their consent. - Patient expressing opposition to participation in the study |
Country | Name | City | State |
---|---|---|---|
France | Assistance Publique Hôpitaux de Marseille | Marseille |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique Hopitaux De Marseille |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate comparatively the quality of the schedules produced by the algorithm developed | to show at least the non-inferiority of this new method compared to the expert user based on the Paddick Index. This index has continuous values between 0 and 1, 0 being the worst case and 1 being the ideal solution | one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04074096 -
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
|
Phase 2 | |
Recruiting |
NCT04474925 -
Pre- Versus Post-operative SRS for Resectable Brain Metastases
|
Phase 3 | |
Recruiting |
NCT05358340 -
Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions
|
N/A | |
Recruiting |
NCT05559853 -
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
|
||
Completed |
NCT03189381 -
Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases
|
N/A | |
Completed |
NCT02082587 -
Toronto BNB Pilot Study
|
N/A | |
Terminated |
NCT01551680 -
A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases
|
Phase 1 | |
Terminated |
NCT00717275 -
Study of Temozolomide to Treat Newly Diagnosed Brain Metastases
|
Phase 2 | |
Recruiting |
NCT05048212 -
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
|
Phase 2 | |
Recruiting |
NCT03714243 -
Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases
|
N/A | |
Recruiting |
NCT05573815 -
Evaluation of Clinical Decision Support System for Brain Metastasis Using Brain MR Images
|
N/A | |
Recruiting |
NCT04899908 -
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
|
Phase 2 | |
Completed |
NCT04507217 -
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
|
Phase 2 | |
Recruiting |
NCT05452005 -
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT06457906 -
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
|
Phase 3 | |
Completed |
NCT04170777 -
Perfexion Registration Using CBCT
|
||
Recruiting |
NCT03027544 -
Tomotherapy for Refractory Brain Metastases
|
N/A | |
Completed |
NCT04178330 -
Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases
|
N/A | |
Terminated |
NCT02187822 -
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
|
Phase 1 | |
Terminated |
NCT00538343 -
RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
|
Phase 2 |